Am J Cancer Res 2020;10(12):4640-4642
www.ajcr.us /ISSN:2156-6976/ajcr0125655

Erratum

Preclinical investigation of ovatodiolide as a potential inhibitor of colon cancer stem cells via downregulating sphere-derived exosomal β-catenin/STAT3/miR-1246 cargoes: Am J Cancer Res. 2020; 10(8): 2337-2354

Yan-Jiun Huang[1,2,3], Tse-Hung Huang[4,5,6], Vijesh Kumar Yadav[7,8], Maryam Rachmawati Sumitra[9], David TW Tzeng[10], Po-Li Wei[1,2], Jing-Wen Shih[9,11,12,13], Alexander TH Wu[11,13,14]

[1]Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 110, Taiwan; [2]Department of Surgery, College of Medicine, Taipei Medical University, Taipei 110, Taiwan; [3]School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan; [4]Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Keelung 204, Taiwan; [5]School of Traditional Chinese Medicine, Chang Gung University, Taoyuan 204, Taiwan; [6]School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei 23741, Taiwan; [7]The Program for Translational Medicine, Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan; [8]Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan; [9]Graduate Institute for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan; [10]School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China; [11]The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan; [12]Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan; [13]Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 110, Taiwan; [14]Graduate Institute of Medical Science, National Defense Medical Center, Taipei 114, Taiwan

Received November 4, 2020; Accepted November 12, 2020; Epub December 1, 2020; Published December 15, 2020

The legends in **Figure 4B** were incorrectly labeled. The dotted lines were labeled as HCT116 (+Exo^{sp}_OV) and HT29 (+Exo^{sp}_OV), respectively. They should have been HCT116 (+Exo^{sp}) and HT29 (+Exo^{sp}).

Address correspondence to: Dr. Jing-Wen Shih, Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan. Tel: +886-2-2697-2035 Ext. 158; E-mail: shihjw@tmu.edu.tw; Dr. Alexander TH Wu, The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan. Tel: +886-2-2697-2035 Ext. 112; E-mail: chaw1211@tmu.edu.tw



Figure 4. Ovatodiolide treatment resulted in less oncogenic exosomes produced by colon cancer tumorspheres. Exosomes, isolated from tumorspheres generated from ovatodiolide-treated (Exo^{sp}) HCT116 and HT29, showed a significantly reduced ability to promote tumorsphere formation (A), 5-FU resistance (B), and migra-

tion (C) when co-cultured with parental HCT116 and HT29 cells. (D) Exo^{sp} cultured normal fibroblasts (NF) showed a lower a-SMA expression (upper panel) and reduced amount of IL-6 released (lower panel) as compared to their Exo^{sp}-cultured counterparts. (E) Real-time PCR analysis of M1 M2 markers post macrophages co-cultured with Exo^{sp} and Exo^{sp} (upper panel). Comparative ELISA of TGF-β1 released by macrophages after co-cultured with Exo^{sp} and Exo^{sp} (lower panel). MΦ, uncommitted macrophages; M1 TAM markers, TNF-α, IL-1β; M2 TAM markers, CD206, TGF-β1. a, $P<0.001$; b, $P<0.01$; NS, no significant difference (all compared to MΦ). *$P<0.05$; **$P<0.01$; ***$P<0.001$.